MedTrace Logo

Safety of NovoMix® 30 or Levemir® for Treatment of Type 2 Diabetics in Macedonia

NCT00842894 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 3421

Last updated 2014-08-15

No results posted yet for this study

Summary

This study is conducted in Europe. The aim of this observational study is to investigate the incidence of serious adverse drug reactions when using NovoMix® 30 (biphasic insulin aspart 30) or Levemir® (insulin detemir) for treatment of type 2 diabetes mellitus under normal clinical practice conditions in Macedonia.

Conditions

Interventions

DRUG

insulin detemir

Safety and effectiveness data collection in connection with the use of the drug.

DRUG

biphasic insulin aspart 30

Safety and effectiveness data collection in connection with the use of the drug in daily clinical practice.

Sponsors & Collaborators

Principal Investigators

  • Global Clinical Registry (GCR, 1452) · Novo Nordisk A/S

Eligibility

Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2009-05-31
Primary Completion
2010-10-31
Completion
2010-10-31

Countries

  • North Macedonia

Study Locations

More Related Trials

Entities

Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00842894 on ClinicalTrials.gov